{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:13:09Z","timestamp":1789985589590,"version":"4.0.1"},"reference-count":59,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>OBJECTIVE. The aim of this study was to determine the relation of medications to the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in children &amp;lt;15 years of age.<\/jats:p>\n               <jats:p>METHODS. We conducted a pooled analysis by using data from 2 multicenter international case-control studies: the severe cutaneous adverse reaction (SCAR) study and the multinational severe cutaneous adverse reaction (EuroSCAR) study conducted in France, Germany, Italy, Portugal, the Netherlands, Austria, and Israel. We selected case subjects aged &amp;lt;15 years, hospitalized for Stevens-Johnson syndrome, Stevens-Johnson syndrome\/toxic epidermal necrolysis-overlap, or toxic epidermal necrolysis, and age-, gender-, and country-matched hospital controls. Pooled crude odds ratios were estimated and adjusted for confounding by multivariate methods when numbers permitted.<\/jats:p>\n               <jats:p>RESULTS. Our study included 80 cases and 216 matched controls. Antiinfective sulfonamides, phenobarbital, carbamazepine, and lamotrigine were strongly associated with the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Significant associations were highlighted in univariate analysis for valproic acid and nonsteroidal antiinflammatory drugs as a group and for acetaminophen (paracetamol) in multivariate analysis.<\/jats:p>\n               <jats:p>CONCLUSIONS. We confirmed 4 previously highly suspected drug risk factors for Stevens-Johnson syndrome\/toxic epidermal necrolysis in children: antiinfective sulfonamides, phenobarbital, carbamazepine, and lamotrigine. Among more unexpected risk factors, we suspect that acetaminophen (paracetamol) use increases the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.<\/jats:p>","DOI":"10.1542\/peds.2008-1923","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T01:54:43Z","timestamp":1232416483000},"page":"e297-e304","source":"Crossref","is-referenced-by-count":213,"title":["Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis"],"prefix":"10.1542","volume":"123","author":[{"given":"Natacha","family":"Levi","sequence":"first","affiliation":[{"name":"Service de Pharmacologie Clinique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bastuji-Garin","sequence":"additional","affiliation":[{"name":"Service de Sante\u0301 Publique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Roujeau","sequence":"additional","affiliation":[{"name":"Service de Dermatologie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Flahault","sequence":"additional","affiliation":[{"name":"Ecole des Hautes Etudes en Sante\u0301 Publique, Paris and Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith P.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Slone Epidemiology Center, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Martin","sequence":"additional","affiliation":[{"name":"Unite\u0301 de Recherche Clinique, Assistance Publique-Ho\u0302pitaux de Paris, Ho\u0302pital Henri Mondor Albert-Chenevier, Cre\u0301teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Slone Epidemiology Center, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maison","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie Clinique"},{"name":"Unite\u0301 de Recherche Clinique, Assistance Publique-Ho\u0302pitaux de Paris, Ho\u0302pital Henri Mondor Albert-Chenevier, Cre\u0301teil, France"},{"name":"Unite U841, Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM), Cre\u0301teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,2,1]]},"reference":[{"key":"2021120822565174600_R1","doi-asserted-by":"crossref","unstructured":"Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med.\u20081994;331(19):1272\u20131285","DOI":"10.1056\/NEJM199411103311906"},{"key":"2021120822565174600_R2","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol.\u20081993;129(1):92\u201396","DOI":"10.1001\/archderm.129.1.92"},{"key":"2021120822565174600_R3","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int.\u20082002;14(4):143\u2013150","DOI":"10.1027\/0838-1925.14.4.143"},{"key":"2021120822565174600_R4","doi-asserted-by":"crossref","unstructured":"Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol.\u20081987;123(9):1160\u20131165","DOI":"10.1001\/archderm.123.9.1160"},{"key":"2021120822565174600_R5","doi-asserted-by":"crossref","unstructured":"Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981\u20131985. Arch Dermatol.\u20081990;126(1):37\u201342","DOI":"10.1001\/archderm.126.1.37"},{"key":"2021120822565174600_R6","unstructured":"Binaghi M, Koso M, Roujeau JC, Coscas G. Ocular complications of Lyell's syndrome: recent concepts apropos of 26 cases [in French]. J Fr Ophtalmol.\u20081985;8(3):239\u2013243"},{"key":"2021120822565174600_R7","doi-asserted-by":"crossref","unstructured":"Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry. J Clin Epidemiol.\u20081996;49(7):769\u2013773","DOI":"10.1016\/0895-4356(96)00035-2"},{"key":"2021120822565174600_R8","doi-asserted-by":"crossref","unstructured":"Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol.\u20081987;123(9):1166\u20131170","DOI":"10.1001\/archderm.123.9.1166"},{"key":"2021120822565174600_R9","doi-asserted-by":"crossref","unstructured":"Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol.\u20081994;102(6):28S\u201330S","DOI":"10.1111\/1523-1747.ep12388434"},{"key":"2021120822565174600_R10","doi-asserted-by":"crossref","unstructured":"Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol.\u20082002;138(8):1019\u20131024","DOI":"10.1001\/archderm.138.8.1019"},{"key":"2021120822565174600_R11","doi-asserted-by":"crossref","unstructured":"Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Aids.\u20082001;15(14):1843\u20131848","DOI":"10.1097\/00002030-200109280-00014"},{"key":"2021120822565174600_R12","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology.\u20082005;64(7):1134\u20131138","DOI":"10.1212\/01.WNL.0000156354.20227.F0"},{"key":"2021120822565174600_R13","doi-asserted-by":"crossref","unstructured":"Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med.\u20081995;333(24):1600\u20131607","DOI":"10.1056\/NEJM199512143332404"},{"key":"2021120822565174600_R14","doi-asserted-by":"crossref","unstructured":"Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet.\u20081999;353(9171):2190\u20132194","DOI":"10.1016\/S0140-6736(98)05418-X"},{"key":"2021120822565174600_R15","doi-asserted-by":"crossref","unstructured":"Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol.\u20081992;26(4):567\u2013574","DOI":"10.1016\/0190-9622(92)70082-Q"},{"key":"2021120822565174600_R16","doi-asserted-by":"crossref","unstructured":"Coopman SA, Stern RS. Cutaneous drug reactions in human immunodeficiency virus infection. Arch Dermatol.\u20081991;127(5):714\u2013717","DOI":"10.1001\/archderm.127.5.714"},{"key":"2021120822565174600_R17","doi-asserted-by":"crossref","unstructured":"Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis.\u20081995;14(6):558\u2013559","DOI":"10.1007\/BF02113442"},{"key":"2021120822565174600_R18","doi-asserted-by":"crossref","unstructured":"Meseguer MA, de Rafael L, Vidal ML. Stevens-Johnson syndrome with isolation of mycoplasma pneumoniae from skin lesions. Eur J Clin Microbiol.\u20081986;5(2):167\u2013168","DOI":"10.1007\/BF02013977"},{"key":"2021120822565174600_R19","doi-asserted-by":"crossref","unstructured":"Stutman HR. Stevens-Johnson syndrome and mycoplasma pneumoniae: evidence for cutaneous infection. J Pediatr.\u20081987;111(6 pt 1):845\u2013847","DOI":"10.1016\/S0022-3476(87)80200-7"},{"key":"2021120822565174600_R20","doi-asserted-by":"crossref","unstructured":"Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics.\u20082007;119(4). Available at: www.pediatrics.org\/cgi\/content\/full\/119\/4\/e1002","DOI":"10.1542\/peds.2006-2401"},{"key":"2021120822565174600_R21","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Buonuomo PS, Maurizi P, Cefalo MP, Corsello M, Riccardi R. Stevens-Johnson syndrome in children receiving phenobarbital therapy and cranial radiotherapy. J Neurooncol.\u20082007;85(2):213\u2013215","DOI":"10.1007\/s11060-007-9399-y"},{"key":"2021120822565174600_R22","doi-asserted-by":"crossref","unstructured":"Maiche A, Teerenhovi L. Stevens-Johnson syndrome in patients receiving radiation therapy. Lancet.\u20081985;2(8445):45","DOI":"10.1016\/S0140-6736(85)90099-6"},{"key":"2021120822565174600_R23","doi-asserted-by":"crossref","unstructured":"Burge SM, Dawber RP. Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus. J Am Acad Dermatol.\u20081985;13(4):665\u2013666","DOI":"10.1016\/S0190-9622(85)80447-3"},{"key":"2021120822565174600_R24","unstructured":"Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol.\u20082003;2(3):278\u2013299"},{"key":"2021120822565174600_R25","doi-asserted-by":"crossref","unstructured":"Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol.\u20081990;23(6 pt 1):1039\u20131058","DOI":"10.1016\/0190-9622(90)70333-D"},{"key":"2021120822565174600_R26","doi-asserted-by":"crossref","unstructured":"Hawk RJ, Storer JS, Daum RS. Toxic epidermal necrolysis in a 6-week-old infant. Pediatr Dermatol.\u20081985;2(3):197\u2013200","DOI":"10.1111\/j.1525-1470.1985.tb01052.x"},{"key":"2021120822565174600_R27","unstructured":"Teillac D, Marsol P, Richard P, et al. Toxic epidermal necrolysis in children (Lyell's syndrome): apropos of 18 cases [in French]. Arch Fr Pediatr.\u20081987;44(8):583\u2013587"},{"key":"2021120822565174600_R28","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol.\u20082008;128(1):35\u201344","DOI":"10.1038\/sj.jid.5701033"},{"key":"2021120822565174600_R29","unstructured":"Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol.\u20082003;30(10):2234\u20132240"},{"key":"2021120822565174600_R30","doi-asserted-by":"crossref","unstructured":"Cochran WG. The comparison of percentages in matched samples. Biometrika.\u20081950;37(3\u20134):256\u2013266","DOI":"10.1093\/biomet\/37.3-4.256"},{"key":"2021120822565174600_R31","unstructured":"Schlesselman JJ. Case Control Studies: Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982"},{"key":"2021120822565174600_R32","doi-asserted-by":"crossref","unstructured":"Hirji K, Tsiatis AA, Mehta CR. Median unbiased estimation for binary data. Am Stat.\u20081989;43(1):7\u201311","DOI":"10.1080\/00031305.1989.10475597"},{"key":"2021120822565174600_R33","doi-asserted-by":"crossref","unstructured":"Horwitz RI, Feinstein AR. The problem of \u201cprotopathic bias\u201d in case-control studies. Am J Med.\u20081980;68(2):255\u2013258","DOI":"10.1016\/0002-9343(80)90363-0"},{"key":"2021120822565174600_R34","doi-asserted-by":"crossref","unstructured":"Hansen RC. Staphylococcal scalded skin syndrome, toxic shock syndrome, and kawasaki disease. Pediatr Clin North Am.\u20081983;30(3):533\u2013544","DOI":"10.1016\/S0031-3955(16)34401-7"},{"key":"2021120822565174600_R35","doi-asserted-by":"crossref","unstructured":"Snyder RA, Elias PM. Toxic epidermal necrolysis and staphylococcal scaled syndrome. Dermatol Clin.\u20081983;1:235\u2013248","DOI":"10.1016\/S0733-8635(18)31042-8"},{"key":"2021120822565174600_R36","doi-asserted-by":"crossref","unstructured":"Maison P, Guillemot D, Vauzelle-Kervroedan F, et al. Trends in aspirin, paracetamol and non-steroidal anti-inflammatory drug use in children between 1981 and 1992 in France. Eur J Clin Pharmacol.\u20081998;54(8):659\u2013664","DOI":"10.1007\/s002280050530"},{"key":"2021120822565174600_R37","doi-asserted-by":"crossref","unstructured":"Sanz E, Hernandez MA, Ratchina S, et al. Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). Eur J Clin Pharmacol.\u20082004;60(2):127\u2013134","DOI":"10.1007\/s00228-004-0739-y"},{"key":"2021120822565174600_R38","doi-asserted-by":"crossref","unstructured":"Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol.\u20081967;79(12):662\u2013671","DOI":"10.1111\/j.1365-2133.1967.tb11434.x"},{"key":"2021120822565174600_R39","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing.\u20081993;22(6):450\u2013456","DOI":"10.1093\/ageing\/22.6.450"},{"key":"2021120822565174600_R40","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, et al. Scorten: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol.\u20082000;115(2):149\u2013153","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"2021120822565174600_R41","doi-asserted-by":"crossref","unstructured":"Golden HE. Stevens-Johnson syndrome associated with herpes simplex virus. Arch Intern Med.\u20081993;153(11):1396","DOI":"10.1001\/archinte.1993.00410110088014"},{"key":"2021120822565174600_R42","doi-asserted-by":"crossref","unstructured":"Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics.\u20081995;5(4):255\u2013258","DOI":"10.1097\/00008571-199508000-00011"},{"key":"2021120822565174600_R43","doi-asserted-by":"crossref","unstructured":"Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf.\u20082002;25(13):965\u2013972","DOI":"10.2165\/00002018-200225130-00006"},{"key":"2021120822565174600_R44","doi-asserted-by":"crossref","unstructured":"Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk\/benefit considerations in adults and children. Epilepsia.\u20081999;40(7):985\u2013991","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"2021120822565174600_R45","doi-asserted-by":"crossref","unstructured":"Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J.\u20082005;35(3):188\u2013190","DOI":"10.1111\/j.1445-5994.2005.00790.x"},{"key":"2021120822565174600_R46","doi-asserted-by":"crossref","unstructured":"Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics.\u20082002;109(1):74\u201378","DOI":"10.1542\/peds.109.1.74"},{"key":"2021120822565174600_R47","unstructured":"Lam NS, Yang YH, Wang LC, Lin YT, Chiang BL. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect.\u20082004;37(6):366\u2013370"},{"key":"2021120822565174600_R48","doi-asserted-by":"crossref","unstructured":"Neuman M, Nicar M. Apoptosis in ibuprofen-induced Stevens-Johnson syndrome. Transl Res.\u20082007;149(5):254\u2013259","DOI":"10.1016\/j.trsl.2006.12.005"},{"key":"2021120822565174600_R49","doi-asserted-by":"crossref","unstructured":"Dore J, Salisbury RE. Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. J Burn Care Res.\u20082007;28(6):865\u2013870","DOI":"10.1097\/BCR.0b013e318159a3c7"},{"key":"2021120822565174600_R50","unstructured":"Kaufman D, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia: The International Agranulocytosis and Aplastic Anemia Study. New York, NY: Oxford University Press; 1991"},{"key":"2021120822565174600_R51","doi-asserted-by":"crossref","unstructured":"Bygum A, Gregersen JW, Buus SK. Acetaminophen-induced toxic epidermal necrolysis in a child. Pediatr Dermatol.\u20082004;21(3):236\u2013238","DOI":"10.1111\/j.0736-8046.2004.21309.x"},{"key":"2021120822565174600_R52","doi-asserted-by":"crossref","unstructured":"Halevi A, Ben-Amitai D, Garty BZ. Toxic epidermal necrolysis associated with acetaminophen ingestion. Ann Pharmacother.\u20082000;34(1):32\u201334","DOI":"10.1345\/aph.19064"},{"key":"2021120822565174600_R53","doi-asserted-by":"crossref","unstructured":"Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J.\u20082001;20(2):219\u2013223","DOI":"10.1097\/00006454-200102000-00022"},{"key":"2021120822565174600_R54","doi-asserted-by":"crossref","unstructured":"Dobrosavljevic D, Milinkovic MV, Nikolic MM. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol.\u20081999;13(1):59\u201361","DOI":"10.1111\/j.1468-3083.1999.tb00846.x"},{"key":"2021120822565174600_R55","doi-asserted-by":"crossref","unstructured":"Shoss RG, Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol.\u20081974;110(5):766\u2013770","DOI":"10.1001\/archderm.110.5.766"},{"key":"2021120822565174600_R56","doi-asserted-by":"crossref","unstructured":"Lonjou C, Borot N, Sekula P, et al. A European study of hla-b in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics.\u20082008;18(2):99\u2013107","DOI":"10.1097\/FPC.0b013e3282f3ef9c"},{"key":"2021120822565174600_R57","doi-asserted-by":"crossref","unstructured":"Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J.\u20082006;6(4):265\u2013268","DOI":"10.1038\/sj.tpj.6500356"},{"key":"2021120822565174600_R58","doi-asserted-by":"crossref","unstructured":"Hunkeler EM, Fireman B, Lee J, et al. Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994\u20132003. J Child Adolesc Psychopharmacol.\u20082005;15(1):26\u201337","DOI":"10.1089\/cap.2005.15.26"},{"key":"2021120822565174600_R59","unstructured":"Slone Epidemiology Center. Patterns of medication use in the United States: 2006. Available at: www.Bu.Edu\/slone\/slonesurvey\/annualrpt\/slonesurveywebreport2006.pdf. Accessed December 15, 2008"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/e297\/1124398\/zpe0020900e297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/e297\/1124398\/zpe0020900e297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:54:01Z","timestamp":1639018441000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/2\/e297\/69374\/Medications-as-Risk-Factors-of-Stevens-Johnson"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-1923","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}